Last reviewed · How we verify
101-PGC-005
At a glance
| Generic name | 101-PGC-005 |
|---|---|
| Sponsor | 101 Therapeutics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 101-PGC-005 for the Treatment of COVID-19 (PHASE2)
- A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care (PHASE2)
- Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 101-PGC-005 CI brief — competitive landscape report
- 101-PGC-005 updates RSS · CI watch RSS
- 101 Therapeutics portfolio CI